Optimized Dosage of Febuxostat Based on its Pharmacological Activity in Hyperuricemia Patients

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K18919
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Medical pharmacy
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Mino Yasuaki 浜松医科大学, 医学部附属病院, 薬剤師 (40586715)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: フェブキソスタット / 体内動態 / 個人間変動

Outline of Final Research Achievements

Xanthine oxidase Inhibitor febuxostat, is believed to its small pharmacokinetic and pharmacodynamic variability. This study aimed to evaluate pharmacokinetic and pharmacodynamic variability of febuxostat and its acyl glucuronide metabolite in clinical settings. A total of 26 patients who were receiving fixed dosage of febuxostat for at least one month were enrolled. Plasma concentration of febuxostat was determined using LC-MS/MS. Acyl glucuronide metabolite of febuxostat was unstable in human plasma and could not be determined in this study. Interindividual variation of plasma concentration of febuxostat was observed. Enzymatic activity of xanthine oxidase in plasma can be evaluated using HPLC-UV. Renal function can affect plasma concentration of febuxostat. Optimized dosage of febuxostat in hyperuricemia patients may be achieved based on plasma concentration of febuxostat and enzymatic activity of xanthine oxidase.

Free Research Field

薬物動態学